180 Wealth Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.62M | Buy |
6,433
+1,702
| +36% | +$366K | 0.16% | 138 |
|
|
2026
Q1 | $1.03M | Buy |
4,731
+1,475
| +45% | +$327K | 0.12% | 189 |
|
|
2025
Q4 | $744K | Buy |
3,256
+570
| +21% | +$130K | 0.08% | 219 |
|
|
2025
Q3 | $622K | Buy |
2,686
+310
| +13% | +$63.1K | 0.08% | 235 |
|
|
2025
Q2 | $441K | Sell |
2,376
-150
| -6% | -$27.9K | 0.06% | 266 |
|
|
2025
Q1 | $529K | Sell |
2,526
-16
| -0.6% | -$3.11K | 0.08% | 222 |
|
|
2024
Q4 | $452K | Buy |
2,542
+63
| +3% | +$11.6K | 0.07% | 240 |
|
|
2024
Q3 | $489K | Sell |
2,479
-7
| -0.3% | -$1.31K | 0.08% | 234 |
|
|
2024
Q2 | $422K | Sell |
2,486
-592
| -19% | -$98.1K | 0.07% | 250 |
|
|
2024
Q1 | $561K | Buy |
3,078
+161
| +6% | +$27.7K | 0.1% | 193 |
|
|
2023
Q4 | $466K | Buy |
2,917
+430
| +17% | +$62.7K | 0.09% | 207 |
|
|
2023
Q3 | $371K | Sell |
2,487
-89
| -3% | -$13.1K | 0.08% | 231 |
|
|
2023
Q2 | $348K | Sell |
2,576
-730
| -22% | -$107K | 0.08% | 232 |
|
|
2023
Q1 | $527K | Sell |
3,306
-88
| -3% | -$13.5K | 0.12% | 178 |
|
|
2022
Q4 | $500K | Buy |
3,394
+227
| +7% | +$34.8K | 0.12% | 191 |
|
|
2022
Q3 | $425K | Buy |
3,167
+13
| +0.4% | +$1.86K | 0.12% | 168 |
|
|
2022
Q2 | $485K | Sell |
3,154
-34
| -1% | -$5.2K | 0.12% | 160 |
|
|
2022
Q1 | $498K | Buy |
3,188
+619
| +24% | +$89.9K | 0.11% | 175 |
|
|
2021
Q4 | $339K | Hold |
2,569
| – | – | 0.08% | 248 |
|
|
2021
Q3 | $281K | Buy |
2,569
+128
| +5% | +$14.6K | 0.06% | 292 |
|
|
2021
Q2 | $280K | Buy |
2,441
+26
| +1% | +$2.93K | 0.06% | 290 |
|
|
2021
Q1 | $280K | Buy |
2,415
+201
| +9% | +$21.5K | 0.07% | 271 |
|
|
2020
Q4 | $248K | Buy |
+2,214
| New | +$213K | 0.07% | 258 |
|
|
2019
Q2 | – | Sell |
-3,445
| Closed | -$269K | – | 248 |
|
|
2019
Q1 | $269K | Sell |
3,445
-2,778
| -45% | -$227K | 0.12% | 207 |
|
|
2018
Q4 | $589K | Sell |
6,223
-106
| -2% | -$9.32K | 0.27% | 110 |
|
|
2018
Q3 | $599K | Sell |
6,329
-2,443
| -28% | -$232K | 0.28% | 110 |
|
|
2018
Q2 | $813K | Buy |
8,772
+2,964
| +51% | +$289K | 0.4% | 75 |
|
|
2018
Q1 | $560K | Buy |
5,808
+3,427
| +144% | +$376K | 0.29% | 108 |
|
|
2017
Q4 | $230K | Buy |
+2,381
| New | +$224K | 0.12% | 205 |
|
Other funds holding ABBV
180 Wealth Advisors's ABBV Position: Q2 2026 in Review
180 Wealth Advisors increased its AbbVie (ABBV) stake by 36% in Q2 2026, buying an estimated $366K and bringing the position to 6,433 shares worth $1.62M. The position accounts for 0.16% of the portfolio, ranked #138.
180 Wealth Advisors first reported a position in ABBV in Q4 2017 and has held it in 29 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- 180 Wealth Advisors held 6,433 shares of AbbVie worth $1.62M as of Q2 2026.
- 180 Wealth Advisors bought 1,702 AbbVie shares in Q2 2026, an estimated $366K.
- AbbVie made up 0.16% of 180 Wealth Advisors's portfolio in Q2 2026, its #138 holding.
- 180 Wealth Advisors first reported a position in AbbVie in Q4 2017 and has held it in 29 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on 180 Wealth Advisors's 13F filing for Q2 2026, filed 7 Jul 2026.